-

INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Frequency, Inc. (NASDAQ: FREQ)

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, has filed a securities class action lawsuit against Frequency, Inc. (NASDAQ: FREQ) (“Frequency” or the “Company”) and its Chief Executive Officer, David Lucchino, alleging violations of §§10(b) and 20(a) of the Securities Exchange Act (15 U.S.C. §§78j(b) and 78t(a)) and Rule 10b-5 promulgated thereunder (17 C.F.R. §240.10b-5). If you purchased Frequency common stock between November 16, 2020, and March 22, 2021, inclusive (the “Class Period”), and have suffered a loss, realized or unrealized, you are encouraged to contact Joe Pettigrew for additional information at 844-818-6982 or jpettigrew@scott-scott.com. The action was filed in the District of Massachusetts and is captioned Evans v. Frequency Therapeutics, Inc., No. 1:21-cv-10933 (D. Mass. June 3, 2021).

Frequency is a pharmaceutical company focused on the development and commercialization of a hearing loss treatment titled “FX-322,” which the Company has long promoted as a potential treatment for patients with severe sensorineural hearing loss (“SNHL”).

The complaint alleges that Frequency and CEO Lucchino misled investors about the Phase 2a study of FX-322.

Before the market opened on March 23, 2021, Frequency disclosed in a press release disappointing interim results of the Phase 2a study, revealing that subjects with mild to moderate SNHL did not demonstrate improvements in hearing measures versus placebo.

On this news, Frequency’s shares fell from $36.29 to $7.99, a 78% drop, damaging investors.

Lead Plaintiff Deadline

The Lead Plaintiff deadline in this action is August 2, 2021. Any member of the proposed Class may seek to serve as Lead Plaintiff through counsel of their choice, or may choose to do nothing and remain a member of the proposed Class.

What You Can Do

If you purchased Frequency common stock between November 16, 2020, and March 22, 2021, or if you have questions about this notice or your legal rights, you are encouraged to contact attorney Joe Pettigrew at 844-818-6982 or jpettigrew@scott-scott.com.

About Scott+Scott

Scott+Scott has significant experience in prosecuting major securities, antitrust, and consumer rights actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Amsterdam, Connecticut, California, Virginia, and Ohio.

This may be considered Attorney Advertising.

Contacts

Joe Pettigrew
Scott+Scott Attorneys at Law LLP
230 Park Avenue, 17th Floor, New York, NY 10169
844-818-6982
jpettigrew@scott-scott.com

Scott+Scott Attorneys at Law LLP

NASDAQ:FREQ

Release Summary
INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Frequency, Inc. (NASDAQ: FREQ)
Release Versions

Contacts

Joe Pettigrew
Scott+Scott Attorneys at Law LLP
230 Park Avenue, 17th Floor, New York, NY 10169
844-818-6982
jpettigrew@scott-scott.com

More News From Scott+Scott Attorneys at Law LLP

CELSIUS HOLDINGS, INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Celsius Holdings, Inc.’s Directors and Officers for Breach of Fiduciary Duties – CELH

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Celsius Holdings, Inc. (NASDAQ: CELH) failed to manage Celsius in an acceptable manner, breaching their fiduciary duties to Celsius, and whether Celsius and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know: On June 4, 2026, the Office of the Texas Attorney Genera...

ADMA BIOLOGICS, INC. INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates ADMA Biologics, Inc.’s Directors and Officers for Breach of Fiduciary Duties – ADMA

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of ADMA Biologics, Inc. (NASDAQ: ADMA) failed to manage ADMA Biologics in an acceptable manner, breaching their fiduciary duties to ADMA Biologics, and whether ADMA Biologics and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know: On March 24, 2026, Culper Research pu...

ZILLOW GROUP, INC. INVESTOR REMINDER: Scott+Scott Attorneys at Law LLP Investigates Zillow Group, Inc.’s Directors and Officers for Breach of Fiduciary Duties – Z, ZG

NEW YORK--(BUSINESS WIRE)--Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Zillow Group, Inc. (NASDAQ: Z, ZG) failed to manage Zillow in an acceptable manner, breaching their fiduciary duties to Zillow, and whether Zillow and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know:On September 30, 2025, the Federal Trade Commission filed a laws...
Back to Newsroom